Patents Assigned to Galephar
-
Patent number: 10709723Abstract: An anti-infective composition for inhalation, containing, at least an effective amount of an antimicrobial aminoglycoside compound or a salt thereof; and an effective amount of a biofilm modifier which is a macrolide compound or salt thereof.Type: GrantFiled: February 17, 2017Date of Patent: July 14, 2020Assignee: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur M. Deboeck, Phillipe Baudier, Francis Vanderbist
-
Publication number: 20180104239Abstract: A spray dried-powder composition for inhalation comprising particles (X) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as sorbitol, mannitol and xylitol; a monosaccharides such as glucose and arabinose; disaccharide such as lactose, maltose, saccharose and dextrose; cholesterol, and any mixture thereof, wherein the composition provides a dissolution rate of said azole derivative of at least, 5% within 10 minutes, 10% within 20 minutes and 40% within 60 minutes when tested in the dissolution apparatus type 2 of the United States Pharmacopoeia at 50 rotation per minute, 37° C. in 900 milliliters of an aqueous dissolution medium adjusted at pH 1.2 and containing 0.3% of sodium laurylsulfate.Type: ApplicationFiled: October 3, 2017Publication date: April 19, 2018Applicant: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur DEBOECK, Francis Vanderbist, Philippe Baudier, Thami Sebti, Christophe Duret, Karim Amighi
-
Publication number: 20170216178Abstract: A dermatological and/or topical composition, which contains retinaldehyde, and DNA.Type: ApplicationFiled: January 27, 2017Publication date: August 3, 2017Applicant: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur M. DEBOECK, Gilbert Mouzin
-
Publication number: 20170087154Abstract: A spray dried-powder composition for inhalation comprising particles (X) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as sorbitol, mannitol and xylitol; a monosaccharides such as glucose and arabinose; disaccharide such as lactose, maltose, saccharose and dextrose; cholesterol, and any mixture thereof, wherein the composition provides a dissolution rate of said azole derivative of at least, 5% within 10 minutes, 10% within 20 minutes and 40% within 60 minutes when tested in the dissolution apparatus type 2 of the United States Pharmacopoeia at 50 rotation per minute, 37° C. in 900 milliliters of an aqueous dissolution medium adjusted at pH 1.2 and containing 0.3% of sodium laurylsulfate.Type: ApplicationFiled: May 16, 2016Publication date: March 30, 2017Applicant: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur DEBOECK, Francis VANDERBIST, Philippe BAUDIER, Thami SEBTI, Christophe DURET, Karim AMIGHI
-
Publication number: 20150231344Abstract: The present invention relates to a pharmaceutical composition for inhalation, consisting in a combination of (A) a dry powder formulation containing a micronized active ingredient, alone or mixed with an inactive ingredient, said powder being filled in a hydroxypropylmethylcellulose (HPMC) capsule and (B) a single dose dry powder inhaler device especially adapted to said capsule to provide a high respiratory dose of said active ingredient when said drug is inhaled by the mouth through said device. Said device being characterized in that he is equipped with piercing needles or pins (in order to pierce the capsule) of diameter of not less than 0.8 mm preferably not less than 1 mm.Type: ApplicationFiled: March 9, 2015Publication date: August 20, 2015Applicant: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur DEBOECK, Francis VANDERBIST, Philippe BAUDIER
-
Patent number: 9089534Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.Type: GrantFiled: December 13, 2012Date of Patent: July 28, 2015Assignee: Galephar Pharmaceutical Research, Inc.Inventors: Francis Vanderbist, Cecile Servais, Philippe Baudier
-
Patent number: 9078925Abstract: The invention relates to an oral pharmaceutical composition of isotretinoin at least two excipients, one of the excipients being a hydrophilic excipient having an HLB value greater than or equal to 10 and the other excipient being an oily vehicle. The oral pharmaceutical composition is substantially devoid of food effect as characterized by a dissolution profile wherein at least 70% of the oral pharmaceutical composition is dissolved after about four hours in a USP2 dissolution apparatus at a paddle speed of 100 rpm, and a dissolution media composed of 900 mL of pH 7.5 buffer containing 0.11% pancreatin, 4.7% cholic acid, 0.14% sodium dihydroxide phosphate and 0.5% sodium hydroxide at 37° C.Type: GrantFiled: December 18, 2013Date of Patent: July 14, 2015Assignee: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur M. DeBoeck, Francis Vanderbist, Cecile Servais, Philippe Baudier
-
Patent number: 8952064Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e.Type: GrantFiled: June 18, 2012Date of Patent: February 10, 2015Assignee: Galephar Pharmaceutical Research, Inc.Inventors: Francis Vanderbist, Cécile Servais, Philippe Baudier
-
Publication number: 20150037414Abstract: A controlled Release Pharmaceutical composition comprising an effective amount of Pravastatin and Fenofibrate, characterised in that the difference, in absolute value, between the times of maximal concentration (Tmax) of Pravastatin and Fenofibric acid is not less than 1.5 hours upon administration with food to humans.Type: ApplicationFiled: July 7, 2010Publication date: February 5, 2015Applicant: GALEPHAR M/FInventors: Arthur M. Deboeck, Philippe Baudier, Francis Vanderbist, Antonio Sereno
-
Publication number: 20150017244Abstract: A spray dried-powder composition for inhalation comprising particles (X) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as sorbitol, mannitol and xylitol; a monosaccharides such as glucose and arabinose; disaccharide such as lactose, maltose, saccharose and dextrose; cholesterol, and any mixture thereof, wherein the composition provides a dissolution rate of said azole derivative of at least, 5% within 10 minutes, 10% within 20 minutes and 40% within 60 minutes when tested in the dissolution apparatus type 2 of the United States Pharmacopoeia at 50 rotation per minute, 37° C. in 900 milliliters of an aqueous dissolution medium adjusted at pH 1.2 and containing 0.3% of sodium laurylsulfate.Type: ApplicationFiled: December 7, 2012Publication date: January 15, 2015Applicant: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur Deboeck, Francis Vanderbist, Philippe Baudier, Thami Sebti, Christophe Duret, Karim Amighi
-
Publication number: 20140107203Abstract: The invention relates to an oral pharmaceutical composition of isotretinoin at least two excipients, one of the excipients being a hydrophilic excipient having an HLB value greater than or equal to 10 and the other excipient being an oily vehicle. The oral pharmaceutical composition is substantially devoid of food effect as characterized by a dissolution profile wherein at least 70% of the oral pharmaceutical composition is dissolved after about four hours in a USP2 dissolution apparatus at a paddle speed of 100 rpm, and a dissolution media composed of 900 mL of pH 7.5 buffer containing 0.11% pancreatin, 4.7% cholic acid, 0.14% sodium dihydroxide phosphate and 0.5% sodium hydroxide at 37° C.Type: ApplicationFiled: December 18, 2013Publication date: April 17, 2014Applicant: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur M. DEBOECK, Francis VANDERBIST, Cecile SERVAIS, Philippe BAUDIER
-
Publication number: 20130330404Abstract: An oral tramadol pharmaceutical composition for once daily administration, containing an effective amount of tramadol or a pharmaceutically-acceptable salt thereof, providing in vivo, a time of tramadol peak plasma concentration (Tmax) greater than 10 hours and a peak tramadol plasma concentration (Cmax) which is less than three times a plasma concentration obtained 24 hours after administration (C24h) of a single dose of the composition.Type: ApplicationFiled: April 17, 2012Publication date: December 12, 2013Applicant: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur M. DEBOECK, Francis VANDERBIST, Antonio SERENO
-
Publication number: 20130217769Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e.Type: ApplicationFiled: December 13, 2012Publication date: August 22, 2013Applicants: GALEPHAR M/FInventors: Francis Vanderbist, Cécile Servais, Phillippe Baudier
-
Patent number: 8367102Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.Type: GrantFiled: August 22, 2007Date of Patent: February 5, 2013Assignee: Galephar Pharmaceutical Research, Inc.Inventors: Francis Vanderbist, Cécile Servais, Phillippe Baudier
-
Publication number: 20110189269Abstract: The present invention relates to a once daily extended release pharmaceutical preparation of Tramadol or its acceptable pharmaceutical salts. The preparation provides, effective blood concentration for a period of about 24 hours with reduced peak concentrations. It is characterized that effective Tramadol levels appear within the first hours after administration, the time to maximal Tramadol content Tmax is at least 10 hours and the peak Tramadol concentration is less than three times the concentration obtained after 24 hours of said administration.Type: ApplicationFiled: November 18, 2010Publication date: August 4, 2011Applicant: GALEPHAR PHARMACEUTICAL RESEARCH, INC.Inventors: Arthur M. Deboeck, Francis Vanderbist, Antonio Sereno
-
Patent number: 7858118Abstract: An oral Tramadol-containing pharmaceutical composition suitable for once daily administration, which contains an amount of Tramadol or a pharmaceutically acceptable salt thereof, providing in vivo, a time of Tramadol peak plasma concentration (Tmax) of greater than 10 hours, and peak Tramadol plasma concentration (Cmax) which are less than three times the plasma concentration obtained 24 hours after administration (C24h) of a single dose of the composition.Type: GrantFiled: April 11, 2002Date of Patent: December 28, 2010Assignee: Galephar Pharmaceutical Research, Inc.Inventors: Arthur M. Deboeck, Francis Vanderbist, Antonio Sereno
-
Publication number: 20100300440Abstract: The present invention relates to a pharmaceutical composition for inhalation, consisting in a combination of (A) a dry powder formulation containing a micronized active ingredient, alone or mixed with an inactive ingredient, said powder being filled in a hydroxypropylmethylcellulose (HPMC) capsule and (B) a single dose dry powder inhaler device especially adapted to said capsule to provide a high respiratory dose of said active ingredient when said drug is inhaled by the mouth through said device. Said device being characterized in that he is equipped with piercing is needles or pins (in order to pierce the capsule) of diameter of not less than 0.8 mm preferably not less than 1 mm.Type: ApplicationFiled: February 16, 2010Publication date: December 2, 2010Applicant: GALEPHAR P.R. INC.Inventors: Arthur Deboeck, Francis Vanderbist, Philippe Baudier
-
Publication number: 20100075913Abstract: A composition for inhalation which contains at least an effective amount of an antimicrobial aminoglycoside compound or a salt thereof, and an effective amount of a biofilm modifier which is a macrolide compound or a salt thereof.Type: ApplicationFiled: April 9, 2009Publication date: March 25, 2010Applicant: Galephar Pharmaceutical Research, Inc.Inventors: Arthur Deboeck, Philipee Baudier, Francis Vanderbist
-
Patent number: 7435427Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.Type: GrantFiled: September 21, 2001Date of Patent: October 14, 2008Assignee: Galephar M/FInventors: Francis Vanderbist, Cecile Servais, Philippe Baudier
-
Publication number: 20080171084Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e.Type: ApplicationFiled: August 22, 2007Publication date: July 17, 2008Applicant: GALEPHAR M/FInventors: Francis VANDERBIST, Cecile SERVAIS, Phillippe BAUDIER